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Liver-derived dendritic cell (DC) progenitors prop-
agated in liquid culture in granulocyte/macrophage 
colony-stimulating factor exhibit low levels both of 
cell surface MIIC class II antigens and of counter-
receptors for CTLA-4ICD28. They fail to stimulate al-
logeneic T cells in mixed leukocyte cultures. To eval-
uate their in vivo functional significance, we 
determined their influence on survival of pancreatic 
islet allografts. Cultured B10.BR (H2k; I-E+) mouse liv-
er-derived DC progenitors were injected (2X106 i.v.) 
into streptozotocin-diabetic BlO (H2b; I-E-) recipients 
7 days before transplantation of pancreatic islets (700 
IEq/mouse) from the same donor strain. No immuno-
suppressive agents were administered. Mean islet al-
lograft survival time was prolonged from 15.3 days (in 
animals pretreated with syngeneic cells) to 30.3 days 
(P<O.OOl) in mice pretreated with the donor-derived 
liver cells. In 20% of these animals, islet allograft sur-
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vival exceeded 60 days. These data suggest that liver-
derived DC progenitors may contribute both to the 
inherent tolerogenicity of the mouse liver and to its 
capacity to protect other allografts of the same donor 
strain from rejection. 
Hepatic allografts are accepted without immunosuppres-
sive therapy when transplanted between many MHC-incom-
patible mouse strains and certain rat strains (1,2). Moreover. 
transplants of the liver protect other organ grafts of the same 
donor or donor strain from rejection (3-7). It has been postu-
lated that this inherent tolerogenicity ofthe liver-a compar-
atively leukocyte-rich organ compared with the kidney or 
heart-is a consequence of donor-recipient leukocyte interac-
tion leading to long-lasting, mutual, immunologic unrespon-
siveness (8, 9). A corollary of this hypothesis is that failure to 
establish and maintain donor cell chimerism results in im-
balanced donor-recipient cell interaction. which may lead to 
graft rejection. Possible effector mechanisms of this two-way 
paradigm have been suggested (10). However, a cellular and 
molecular basis for interactions that may predispose to the 
development of mutual, donor-recipient immunologic nonre-
activity has not been elucidated. 
In the multilineage cell chimerism that has been described 
in recipient tissues following transplantation of the liver or 
other organs, donor-derived dendritic cells (DC"') known to 
• Abbreviations: CR. counter-receptor; DC. dendritic cell: GM-CSF. 
granulocyte-macrophage colony-stimulating factor: hpf, high power field; 
MLC. mixed leukocyte culture; NPC. nonparenchymal cell. 
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migrate to secondary lymphoid tissue (11) have been fea-
tured prominently (1, 9, 12). Although the DC resident in 
normal lymphoid tissue are potent antigen-presenting cells 
(13), freshly-isolated DC from commonly transplanted non-
lymphoid tissues, such as the liver, kidney, or heart, are 
functionally "immature" (13, 14), Their maturation is 
thought to reflect the up-regulation by cytokines of both 
MHC gene product and costimulatory molecule expression 
(15). It has been suggested (8, 16) that these costimulatory 
molecule-deficient DC may constitute potentially tolerogenic 
precursors of the chimeric leukocytes seen in organ graft 
recipients. The magnitude, tissue-specific site dependency, 
replicative capacity, or maturational stage of chimeric DC 
that might be necessary to mediate postulated tolerizing 
effects has not been established. 
Recently, we have succeeded in propagating DC progeni-
tors from normal mouse liver in response to granulocyte/ 
macrophage colony stimulating factor (GM-CSF) (17). Fol-
lowing local or systemic injection, these cells migrate to 
T-dependent areas of allogeneic host lymphoid tissue, and 
express cell surface donor MHC class II. They persist indef-
initely, although in diminished numbers (18). Furthermore, 
in spontaneously tolerant liver transplant recipients (but not 
in animals rejecting donor strain hearts), donor-derived DC 
can be propagated from host bone marrow and spleen using 
GM-CSF (19). These observations have raised questions 
about the functional significance ofGM-CSF-stimulated, do-
nor-derived DC progenitors in allograft recipients, and their 
possible relation to liver tolerogenicity. The potential of ex-
ploiting these putative tolerogenic cells for the therapy of 
graft rejection has also been suggested (16, 17). 
In this study, we have examined whether systemic injec-
tion ofGM-CSF-stimulated, liver-derived DC progenitors can 
affect the survival of subsequent (pancreatic islet) allografts 
from the same donor strain. The results show that the liver-
derived cells, but not "mature" GM-CSF-stimulated spleen-
derived DC, significantly prolong islet transplant survival. 
They suggest a possible role of donor-derived, GM-CSF-re-
sponsive DC progenitors in allograft acceptance that may be 
related to the inherent tolerogenicity of the liver. 
Animals. Adult 8- to 12-week-old male B10.BR <H2k, I-E+) 
mice and C57BU10SnJ (B10, H2b , I-A +) mice were pur-
chased from The Jackson Laboratory, Bar Harbor, ME. They 
were maintained in the specific pathogen-free facility of the 
University of Pittsburgh Medical Center. 
Isolation of nonparenchymal cells (NPC) from mouse liver. 
NPC were isolated from normal B10.BR mouse livers follow-
ing in situ perfusion, digestion in collagenase solution, and 
Percoll centrifugation, as described in detail elsewhere (17). 
For comparative purposes, fresh spleen cell populations 
were prepared using the same protocol. 
Culture of liver· and spleen·derived DC lineage cells with 
GM·CSF. Liver NPC or spleen cells (2.5X106/welll were 
placed in 24-well plates containing 2 ml of RPMI-1640 com-
plete medium (Gibco, Grand Island, NY) supplemented with 
10% v/v fetal calf serum, and 0.4 ng/ml recombinant mouse 
GM-CSF (R&D Systems, Minneapolis, MN). Nonadherent, 
low buoyant density cells released from developing clusters 
were propagated as described (17). Cells were harvested for 
study after 7-10 days culture. 
Flow cytometric analysis. Immunophenotypic analysis of 
GM-CSF-stimulated liver- or spleen-derived cells was per-
formed by either direct or indirect immunofluorescence stain-
ing using an extensive panel of mAbs, as detailed elsewhere 
(17). The mAbs included antibodies directed against mouse 
lymphoid, myeloid, or DC-restricted markers (33D1, TIB227; 
ATCC, NLDC-145; and CDllc, N418; kindly provided by Dr. 
R.M. Steinman, Rockefeller University, New York, NY). In 
addition, counter-receptors (Cm of CTLA-4 (a structural ho-
molog of CD28) (CTLA-4CRl, which include B7 family mem-
bers CD80 (B7-D and CD86 (B7-2), were identified using the 
CTLA-4Ig fusion protein (a gift from Dr. P.S. Linsley, Bristol 
Myers Squibb Pharmaceutical Research Institute, Seattle, 
WAl, with human Ig (Sigma Chemical Co., St. Louis, MOl as 
a negative control. Flow cytometric analysis was performed 
using a FACSTAR flow cytometer (Becton Dickinson, San 
Jose, CAl. Five thousand events were acquired for each sam-
ple. 
Mixed leukocyte cultures (MLC). MLC were performed in 
96-well, round-bottom microculture plates with variable 
numbers ofGM-CSF-stimulated, y-irradiated (20 Gy) alloge-
neic (B10.BR) or syngeneic (BIO) liver- or spleen-derived cells 
as stimulators. B10 spleen cells (4X105/well) enriched for T 
cells by passage (1 hr) through a nylon wool column were 
used as responders. Cultures were maintained for 72 hr; 
[3H]TdR (1 /J.Cilwell) was added 18 hr before harvesting and 
the extent of DNA synthesis was determined by liquid scin-
tillation counting. 
DC migration. Cultured B10.BR liver-derived DC progen-
itors were washed in RPMI 1640 and injected subcutaneously 
(2.5X 105 in 0.05 ml) into the left hind footpad of naive B10 
recipients. One to 60 days later, the mice were killed and 
their spleens were removed and embedded in Tissue-Tek 
(O.C.T. compound, Miles Inc., Elkhart, IN). Cryostat sections 
(10 /J.m) were cut, processed, and stained for donor MHC class 
II (I-Ek)-positive cells, as described (18). The mean number of 
positive cells per 100 high power fields (hpf) was determined. 
In vivo treatment protocol. Naive B10 mice were rendered 
diabetic (blood glucose >250 mg/dl) by intravenous injection 
of streptozotocin (Sigma, 200 mglkg). Two days later, 2x 106 
BIO.BR-derived, GM-CSF-stimulated, liver- or spleen-de-
rived cells were injected intravenously (tail vein). Seven days 
after injection of cultured cells, and with daily monitoring 
and treatment with insulin (beef-pork insulin [regular Iletin 
I, Eli Lilly and Co., Indianapolis IN]; 1-2 IU i.p./mouse), the 
animals underwent pancreatic islet transplantation. 
Islet cell isolation and purification. Fresh B10.BR islets 
were isolated by a modification of the automated method 
described previously (20). Briefly, after cannulation of the 
pancreatic ducts of heart-beating donors, collagenase solu-
tion (Boehringer-Mannheim, type P; 0.7 mg/ml) was injected 
at 4°C and a pancreatectomy was performed. The pancreata 
were loaded into a stainless steel digestion chamber and the 
islets were isolated by a continuous digestion process that 
lasted IO::t3 min. With gentle shaking, the solution contain-
ing collagenase was recirculated (flow rate 85 ml/min) 
through the chamber. The process of digestion was initiated 
by raising the temperature of the solution at the rate of 
2°C/min by passing it through a stainless steel coil immersed 
in a 45°C water bath until it reached 37-38°C. Digestion was 
monitored by sample harvesting every 2 min, staining with 
dithizone (Sigma), and light microscopic examination. When 
"free islets" were observed, the digestion was interrupted and 
the isolated cells were collected. The islets were then purified 
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by centrifugation in a cell processor (COBE 2991, Lakewood, 
CO) using discontinuous density gradients (densities of 
1.108, 1.096, and 1.037). 
Islet transplantation. Seven days after the infusion ofGM-
CSF-stimulated cells or culture media, 700 isolated BI0.BR 
islets (purity 90:t5%) with an average individual diameter of 
150 I'- (1 IEq) were placed beneath the left renal capsule of 
each diabetic B10 recipient (only animals with blood glucose 
levels >350 mg/dl were used). Blood glucose was monitored 
daily for the fIrst 15 days after transplantation and every 
other day thereafter. Rejection of islet allografts was consid-
ered to have taken place when the blood glucose exceeded 250 
mg/dl on two consecutive measurements. Body weight was 
also monitored as an overall index of physiologic status. 
Statistics. Median graft survival times between groups of 
transplanted animals were compared using the Kruskal-
Wallis test, a nonparametric equivalent to the one-way anal-
ysis of variance. Pair-wise comparisons were performed us-
ing the Wilcoxon rank sum test. A P-value <0.05 was 
considered statistically signiflcant. 
Liver-derived cells harvested after 7-10 days of culture in 
GM-CSF expressed surface antigens associated with mouse 
DC, including CD45 (leukocyte common antigen), heat stable 
antigen, CD54 (intercellular adhesion molecule-I), CDllb 
(MAC-I), and CD44 (nonpolymorphic determinant of Pgp.1 
RatmAbs 
LOG FLUORESCENCE INTENSITY 
glycoprotein) (Fig. 1). In addition, staining of weak to mod-
erate intensity was observed for the DC-restricted markers 
NLDC-145 (interdigitating cells), 33D1, and CDllc (N418) 
and for F4/80 and CD32 (FcyRII). Expression ofT cell (CD3), 
B cell (B220), and NK cell markers (NK1.1 and LGL-1) was 
absent. The GM-CSF-stimulated spleen-derived cells were 
similar, except that CD32 and CDllb were reduced com-
pared with the liver-derived cells (data not shown). In con-
trast to the spleen cell progeny which were MHC class IIbright 
and strongly positive for CTLA-4CR, the liver-derived, GM-
CSF-stimulated cells were MHC class II(I_Ek)dim (Fig. 1) and 
did not express detectable levels of cell surface CTLA-4CR. 
The GM-CSF-stimulated BI0.BR spleen-derived DC, 
which expressed high levels both of cell surface MHC class II 
antigen and CTLA-4CR, were potent stimulators of naive 
allogeneic (BI0) T cells at low S:R ratios in 3-day MLCs 
(Table 1). In contrast, the B10.BR liver-derived DC progeni-
tors failed to stimulate B10 splenic T cells. 
Following the injection of GM-CSF -stimulated liver DC 
progenitors into unmodifIed naive allogeneic recipients, do-
nor MHC class 11+ (I-Ek+) cells with distinct dendritic mor-
phology were fIrst observed in the spleen 24 hr later 
(3.97:±:2.11 cellS/100 hpf). Maximal numbers of I-Ek+ cells 
were found on day 5 (15.81:t8.97/100 hpf). Thereafter, the 
mean number declined (10.91:t0.73/100 hpf at 2 weeks), but 
FIGURE 1. FACSCAN immunophenotypic profile 
of GM-CSF-stimulated BIO.BR mouse liver-de-
rived cells with DC characteristics released from 
cell aggregates (culture day 8) and exammed us-
ing rat, hamster. or mouse mAbs. Note the ab-
sence of lymphoid cell markers and the low level 
of MHC class II (l_Ek) expression. The result is 
representative of 6 separate experiments. 
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TABLE 1. Allostimulatory activity of GM-CSF-stimulated. BIO.BR liver-derived DC progenitors and spleen-derived DC in primary MLC 
Stimulators cpm (XI03 ) 
S:R ratio· 
Spleen cells Liver DC progenitors Spleen-derived DC 
(Iyngeneic) (allogeneic) (allogeneic) 
1:3 3.86 ± 0.36 4.06 ± 0.54 45.49 ± 1.53 
1:9 5.48 ± 1.87 3.80 ± 0.26 27.29 ± 0.10 
1:27 5.47 ± 1.24 5.75 ± 0.92 18.56 ± 4.39 
1:81 5.60'" 1.28 7.58 ± 1.60 9.40 ± 0.40 
a For the stimulator:responder cell ratio, 400,000 BI0 splenic T cells were stimulated for 3 days with various numbers of -y-irradiated 
syngeneic <BI0) or allogeneic <BI0.BR) stimulator cells. 
I_Ek+ cells were still detected in T cell areas at least 2 months 
after the injection of liver-derived DC progenitors. 
These experiments were extended to evaluate whether the 
systemic inoculation of GM-CSF-stimulated, donor-derived 
liver DC progenitors could reduce responsiveness to islet 
allografts, thus prolonging their survival. The results ob-
tained from two experiments (Fig. 2) show that intravenous 
injection of 2x 106 BlO.BR liver DC progenitors into BIO mice 
2 days after the animals were rendered diabetic (group 3) 
significantly prolonged the mean survival time of allogeneic 
islets transplanted 7 days later. Mean survival time was 
extended from 15.3=0.7 days (syngeneic control; group 2) to 
30.3 = 17.1 days (group 3; P<O.OOl). The liver DC progenitors 
syngeneic with the host (group 2) slightly prolonged islet 
allograft survival compared with media alone (group 1; 
11.9=0.9 days). In contrast, islet graft recipients pretreated 
with cultured donor strain (B10.BR) spleen-derived DC 
(group 4) rejected their grafts within approximately the same 
time (12.0=2.0 days) as media-treated diabetic controls 
(group 1). 
Examination of the spleens of mice whose islet graft sur-
vival was prolonged as the result of allogeneic liver cell 
injection (group 3) revealed small numbers of isolated donor 
class II+ !I_Ek +) cells. As reported previously for normal 
recipients US), these dendritic-shaped cells were detected in 
close proximity to arterioles in T-dependent areas and were 
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FIGURE 2. Influence of cultured B 1O.BR liver DC progenitors on 
BlO.BR pancreatIc islet allograft sUl"V1val in B 10 mIce. Cultured 
liver IU- or spleen IS)-derived cells 12>< 10';) were injected intrave-
nously 2 days after the recipIent animals were made diabetic WIth an 
intraperitoneal injection of streptozotocin 1200 mglkg). The animals 
were maintained on Insulin. as described in Materla/s and Methods 
11-2 IV i.p. daily). until pancreatic islet transplantation. Pancreatic 
islets 1700 IEq/mouse, were placed beneath the left renal capsule 7 
days after the injection of cultured GM-CSF-stimulated liver DC 
progenitors or spleen-derived DC. 
not observed in islet allograft recipients pretreated with syn-
geneic, liver-derived DC progenitors (group 2). This rendered 
unlikely the possibility that these chimeric cells were derived 
from the islet allograft. 
There has been recent speculation that bone marrow-de-
rived DC progenitors or costimulatory molecule-deficient 
"immature" DC present in commonly transplanted nonlym-
phoid organs, such as the liver, kidney, or heart, may consti-
tute potentially tolerogenic precursors of chimeric cells ob-
served in allograft recipients. We have observed that DC 
progenitors grown from liver NPC in response to low concen-
trations of GM-CSF fail to stimulate naive allogeneic T cells 
in MLC. As shown elsewhere, however (17), these DC pro-
genitors can be induced to mature into potent allostimulatory 
cells by continued exposure to GM-CSF in the presence of 
type-l collagen, an extracellular matrix protein with which 
they are spacially associated in normal liver. 
After transplantation of the liver or other nonlymphoid 
organs, emigrant DC progenitors may undergo in vivo prolif-
eration/differentiation/maturation within recipient tissues 
(as evidenced in this study and elsewhere [17] by the up-
regulation of donor MHC class II expression). This is likely to 
be influenced (both positively and negatively) by endogenous 
GM-CSF and other cytokines (e.g., IL-1, TNF-a, IL-4, IL-12, 
and c-kit ligand). The nature and kinetics of this process, 
however, are also likely to be affected by host immunosup-
pression, particularly the use of potent inhibitors either of 
cytokine production le.g., tacrolimus or cyc1osporine) or of 
responses of leukocytes to growth/differentiation factors . 
There are several possible reasons for the transitory na-
ture of the therapeutic effect achieved with liver-derived DC 
progenitors in this study. These include insufficient num-
bers/frequency or suboptimal timing of the liver cell admin-
istration, and alterations in levels of micro-environmental 
b'Towth factors. Furthermore. in the absence of immunosup-
pressive therapy, cytokine-induced in vivo functional matu-
ration of donor-derived DC progenitors may have contributed 
to the eventual rejection of the allografted islets. The pOSSIble 
tolerogenic implications of the rapid migration from the liver 
I a potential hematolymphoid organ). or from other trans-
planted whole organs. of GM-CSF-responsive DC precursors 
deficient in T cell costimulatory molecules are considerable. 
The implications are emphasized by the lengthy persistence 
of these donor-derived cells in nonimmunosuppressed alloge-
neic mouse recipients (18), and by the capacity of the cells to 
prolong survival of (islet) allografts from the same donor 
strain. Furthermore, propagation of donor-derived DC pre-
cursors from the lymphoid tissue of spontaneously tolerant 
mouse liver allograft recipients in response to GM-CSF (19) 
--------.---~---~ ----------
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provides a mechanistic basis for the perpetuation of leuko-
cyte chimerism in recipients of liver and other organ grafts. 
The possible mechanistic role of chimeric DC or other lin-
eages and their progeny in the establishment of donor-spe-
cific unresponsiveness remains to be defined. We have shown 
elsewhere that immunologically "immature" DC (MHC class 
II+, B7-1 +, B7-2-) propagated from mouse bone marrow can 
induce alloantigen-specific T cell hyporesponsiveness in vitro 
(21). Moreover, a subpopulation of mouse DC with veto func-
tion (inactivation of T helper cells or cytotoxic T cell precur-
sors) has been identified (22). Furthermore, it has been pos-
tulated that MHC class IIdim allogeneic donor bone marrow 
cells that exhibit veto cell activity are immature DC (23). The 
precise basis of DC-T cell interactions that might lead to 
tolerance induction is uncertain. It is likely, however, to 
depend on the relative affinity or avidity (compared with 
"immunizing" antigen-presenting cells) of donor DC-T cell 
receptor interactions and on the expression on the former 
cells of critical adhesins and costimulatory molecules, such as 
members of the intercellular adhesion molecule and B7 fam-
ilies and CD40. These aspects of developing liver- and bone 
marrow-derived DC both in vitro and in vivo are under fur-
ther investigation. 
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